Soley Therapeutics Develops First-in-Class CKAP2 Modulator STX-6398 for Cancer Treatment
核心洞察
Soley Therapeutics (搜索) has developed STX-6398 (搜索), a first-in-class oral small molecule that targets CKAP2 (搜索), a previously undruggable protein central to malignant cancer progression.
Preclinical studies demonstrate selective anti-tumor activity both in vitro and in vivo across multiple cancer models following oral administration.
The company will present comprehensive preclinical data at the AACR Annual Meeting 2026, showcasing their integrated cell stress biology platform's ability to drug previously inaccessible targets.
Soley Therapeutics (搜索) has announced the development of STX-6398 (搜索), a first-in-class oral small molecule drug candidate that targets cytoskeleton-associated protein 2 (搜索) (CKAP2 (搜索)), marking a significant breakthrough in targeting a previously undruggable protein central to malignant cancer progression. The South San Francisco-based biotechnology company will present comprehensive preclinical data at the American Association for Cancer Research Annual Meeting 2026 in San Diego.
Novel Target Validation
STX-6398 (搜索) represents a pioneering approach to cancer treatment by modulating CKAP2 (搜索) and its downstream signaling pathways. According to the company's research, CKAP2 sits at the critical intersection of microtubule dynamics and malignant progression, directly influencing cancer cell proliferation, migration, and angiogenesis. This protein has historically been considered undruggable, making Soley's achievement particularly noteworthy in the oncology field.
"CKAP2 (搜索) sits at the intersection of microtubule dynamics and malignant progression, shaping proliferation, migration, and angiogenesis," said Yerem Yeghiazarians, M.D., Co-Founder and Chief Executive Officer of Soley Therapeutics (搜索). "The data to be presented at AACR demonstrate that it is possible to pharmacologically modulate CKAP2 with an oral small molecule and achieve meaningful anti-tumor activity across multiple preclinical models."
Preclinical Efficacy Data
The preclinical studies demonstrate selective anti-tumor activity both in vitro and in vivo, with efficacy observed across multiple preclinical models following oral administration. These findings support the advancement of STX-6398 (搜索) as a new therapeutic opportunity specifically for CKAP2 (搜索)-expressing cancers. The oral bioavailability of the compound represents an additional advantage for potential clinical development and patient convenience.
Platform Validation
STX-6398 (搜索) serves as validation for Soley Therapeutics (搜索)' proprietary drug discovery platform, which translates cell stress biology into first-in-class drug candidates. The successful development of this CKAP2 (搜索) modulator demonstrates the platform's capability to enable drugging of targets that were previously considered inaccessible to pharmaceutical intervention.
"STX-6398 (搜索) is one of many first-in-class candidates from Soley's integrated cell stress platform and validates that our approach can enable drugging targets long considered inaccessible," Yeghiazarians noted.
AACR 2026 Presentation
The company will present detailed findings on the discovery and preclinical characterization of STX-6398 (搜索) at the AACR Annual Meeting 2026. The presentation, titled "CKAP2 (搜索) Modulation with a Novel Small Molecule Results in Excellent In-Vitro and In-Vivo Anti-Tumor Activity," is scheduled for April 20, 2026, from 2:00 PM to 5:00 PM PDT in Poster Section 15. The data will be presented under the Experimental and Molecular Therapeutics session category, specifically focusing on Novel Targets and Pathways.